These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 6295890)

  • 21. Cytokeratin 5 and estrogen receptor immunohistochemistry as a useful adjunct in identifying atypical papillary lesions on breast needle core biopsy.
    Grin A; O'Malley FP; Mulligan AM
    Am J Surg Pathol; 2009 Nov; 33(11):1615-23. PubMed ID: 19675450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma.
    de Candia P; Akram M; Benezra R; Brogi E
    Hum Pathol; 2006 Aug; 37(8):1032-41. PubMed ID: 16867866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistologic detection of estrogen receptors in paraffin-embedded breast cancers: correlation with cytosol measurements.
    Pascal RR; Santeusanio G; Sarrell D; Johnson CE
    Hum Pathol; 1986 Apr; 17(4):370-5. PubMed ID: 3007325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of hormone receptors with pathological features in human breast cancer.
    Millis RR
    Cancer; 1980 Dec; 46(12 Suppl):2869-71. PubMed ID: 6256055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In situ distribution of oncogene products and growth factor receptors in breast carcinoma: c-erbB-2 oncoprotein, EGFr, and PDGFr-beta-subunit.
    Kommoss F; Colley M; Hart CE; Franklin WA
    Mol Cell Probes; 1990 Feb; 4(1):11-23. PubMed ID: 1969111
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Estrogen receptor status of breast cancer patients].
    Winzer KJ; Saul G; Sinn B; Kranz D; Wolff H; Rose H
    Zentralbl Chir; 1986; 111(15):915-20. PubMed ID: 3020841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Histological identification of carcinoembryonic antigen in breast cancer. Use of an immunohistochemical technique in 71 cases of breast cancer (author's transl)].
    Bonetti F; Maconi A; Pisa R; Menestrina F; Novelli P; Iannucci A; Chilosi M; Rasniewskij K
    Pathologica; 1981; 73(1026):639-47. PubMed ID: 6273781
    [No Abstract]   [Full Text] [Related]  

  • 28. Frequency of subtypes of biliary intraductal papillary mucinous neoplasm and their MUC1, MUC2, and DPC4 expression patterns differ from pancreatic intraductal papillary mucinous neoplasm.
    Sclabas GM; Barton JG; Smyrk TC; Barrett DA; Khan S; Kendrick ML; Reid-Lombardo KM; Donohue JH; Nagorney DM; Que FG
    J Am Coll Surg; 2012 Jan; 214(1):27-32. PubMed ID: 22112419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical value of the wild-type estrogen receptor beta expression in breast cancer.
    Omoto Y; Inoue S; Ogawa S; Toyama T; Yamashita H; Muramatsu M; Kobayashi S; Iwase H
    Cancer Lett; 2001 Feb; 163(2):207-12. PubMed ID: 11165756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The mucinous variant of columnar cell lesions.
    Verschuur-Maes AH; Van Diest PJ
    Histopathology; 2011 May; 58(6):847-53. PubMed ID: 21585423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of estrogen receptor in breast and endometrial carcinoma by the immunoperoxidase technique.
    Taylor CR; Cooper CL; Kurman RJ; Goebelsmann U; Markland FS
    Cancer; 1981 Jun; 47(11):2634-40. PubMed ID: 6167343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cytochemical determination of estrogen receptors in breast tumors].
    Winzer KJ; Kranz D; Enzmann G
    Zentralbl Chir; 1987; 112(18):1155-9. PubMed ID: 2825448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast.
    Baqai T; Shousha S
    Histopathology; 2003 May; 42(5):440-7. PubMed ID: 12713620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast.
    Ichihara S; Fujimoto T; Hashimoto K; Moritani S; Hasegawa M; Yokoi T
    Pathol Int; 2007 Mar; 57(3):126-32. PubMed ID: 17295644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters.
    Naidu R; Wahab NA; Yadav MM; Kutty MK
    Oncol Rep; 2002; 9(2):409-16. PubMed ID: 11836618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinicopathologic and prognostic evaluation of invasive breast carcinoma molecular subtypes and GATA3 expression.
    Demir H; Turna H; Can G; Ilvan S
    J BUON; 2010; 15(4):774-82. PubMed ID: 21229645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Solid papillary carcinoma of the breast. A form of intraductal carcinoma with endocrine differentiation frequently associated with mucinous carcinoma.
    Maluf HM; Koerner FC
    Am J Surg Pathol; 1995 Nov; 19(11):1237-44. PubMed ID: 7573685
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component.
    Yu KD; Wu LM; Liu GY; Wu J; Di GH; Shen ZZ; Shao ZM
    Ann Surg Oncol; 2011 May; 18(5):1342-8. PubMed ID: 21042943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of immunocytochemically demonstrated estrogen receptor distribution and histopathologic features in primary breast cancer.
    Berger U; Wilson P; McClelland RA; Davidson J; Coombes RC
    Hum Pathol; 1987 Dec; 18(12):1263-7. PubMed ID: 2824329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.